Pfizer ready for post-COVID gains

Article Excerpt

Pfizer’s COVID-19 vaccine has generated big gains for investors. While demand is now fading as the pandemic eases, new booster shots that target the Omicron variant should continue to spur its profits. The company is using its higher earnings to buy smaller drugmakers. Pfizer’s expertise should accelerate the commercialization of these promising new drugs and offset the expected drop in COVID-19 vaccine sales. That should let the company continue to raise your dividend. PFIZER INC. $44 is your #1 Income Buy for 2022. The company (New York symbol PFE; Income Portfolio, Manufacturing & Industry sector; Shares outstanding: 5.6 billion; Market cap: $246.4 billion; Price-to-sales ratio: 2.5; Dividend yield: 3.6%; TSINetwork Rating: Above Average; www.pfizer.com) began operating in 1849 and is now one of the world’s largest makers of prescription drugs. Its top-selling brands include Eliquis (stroke), Ibrance (breast cancer) and Prevnar (pneumonia). In response to the COVID-19 pandemic, Pfizer teamed up with German drugmaker BioNTech (Nasdaq symbol BNTX) to develop a vaccine using messenger ribonucleic acid…